Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Capricor Therapeutics (CAPR) over the last 12 years, with Q3 2025 value amounting to $494725.0.

  • Capricor Therapeutics' Depreciation and Depletion rose 3697.96% to $494725.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 2984.58%. This contributed to the annual value of $1.4 million for FY2024, which is 3333.69% up from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' Depreciation and Depletion is $494725.0, which was up 3697.96% from $486278.0 recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Depreciation and Depletion high stood at $494725.0 for Q3 2025, and its period low was $49054.0 during Q1 2021.
  • Over the past 5 years, Capricor Therapeutics' median Depreciation and Depletion value was $254702.0 (recorded in 2023), while the average stood at $245116.4.
  • Per our database at Business Quant, Capricor Therapeutics' Depreciation and Depletion surged by 14878.47% in 2023 and then soared by 2213.76% in 2024.
  • Capricor Therapeutics' Depreciation and Depletion (Quarter) stood at $78645.0 in 2021, then skyrocketed by 143.63% to $191602.0 in 2022, then skyrocketed by 60.55% to $307608.0 in 2023, then increased by 22.14% to $375705.0 in 2024, then surged by 31.68% to $494725.0 in 2025.
  • Its last three reported values are $494725.0 in Q3 2025, $486278.0 for Q2 2025, and $405450.0 during Q1 2025.